Malignant NeoplasmEarly Phase 1NCT07707999
Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors
A Early Phase 1 study testing Novel FAP-targeted probe in people with Malignant Neoplasm, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
Trial summary
This study is a single-center, open-label first-in-human clinical study. Patients with clinically suspected or confirmed malignant solid tumors will undergo [68Ga]Ga-FAP PET imaging or [177Lu]Lu-FAP SPECT imaging as well as [18F]FDG PET imaging to determine the presence or absence of lesions, and to assess lesion… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Malignant Neoplasm
- What is being tested?
- Novel FAP-targeted probe
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 20 participants
- Where
- 1 siteChina
- Study dates
- 30 Jul 2026to 30 Dec 2026
- Phase
- Early Phase 1
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Voluntary participation and the patient or their legal representative is able to sign an informed consent form.
- Adult patients (aged 18 or above), regardless of gender.
- Patients with an ECOG performance status of 0 to 1 and able to tolerate PET and SPECT/CT examinations.
- Patients with histopathologically or clinically confirmed malignant solid tumors who have measurable lesions according to RECIST 1.1 criteria.
- Patients with expected survival>6 months.
- Female patients of childbearing potential must have a negative pregnancy test, and all patients (including male patients) agree to use effective contraceptive measures during the study period and for at least three months after study drug administration.
Who cannot join
- Patients who are pregnant or breastfeeding, or plan to become pregnant during the study period or within three months after study drug administration (excluding those who have been postmenopausal for at least one year, or those who are surgically sterilized, such as bilateral tubal ligation without recanalization, bilateral oophorectomy, or hysterectomy); or patients who plan to donate sperm or eggs during the study period or within three months after study drug administration.
- Patients with known or suspected allergy to the investigational drug or any of its components, or patients with severe allergic constitution.
- Patients who have undergone procedures within 6 months prior to study entry that, in the investigator's judgment, may affect drug absorption, distribution, metabolism, or excretion.
- Patients with positive syphilis or HIV test results at screening.
- Patients with abnormal liver or kidney function: serum total bilirubin (TBIL) > 31.5 umol/L; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 120 U/L, or > 200 U/L if the elevation is considered to be related to liver metastases from solid tumors; serum creatinine (Scr) > 150 umol/L, or creatinine clearance < 60 mL/min (according to the Cockcroft-Gault formula).
- Patients with abnormal bone marrow parameters: absolute neutrophil count < 1.5 x 10^9/L, hemoglobin < 10 g/dL, serum albumin < 2.8 g/dL (normal range 3.5-5.5 g/dL), platelets < 100 x 10^9/L (normal range 100-300 x 10^9/L), international normalized ratio (INR) > 1.5 (normal range 0.8-1.3) in patients not taking warfarin, or prothrombin time (PT) > 2 x ULN (normal range 11-15 seconds).
Show all 12Show fewer
- Patients with active infection (e.g., acute bacterial infection, tuberculosis, active hepatitis B/C, active syphilis, etc.). Active hepatitis B is defined as: positive HBsAg or HBcAb, or results outside the normal reference range, accompanied by hepatitis B virus DNA titer > 2500 copies/mL or > 500 IU/mL. Active hepatitis C is defined as: positive hepatitis C antibody, or results outside the normal reference range, and positive HCV-RNA.
- Patients with dysuria or urinary incontinence due to any cause.
- Patients with claustrophobia or other conditions that preclude cooperation with PET/MR and SPECT/CT examinations.
- Patients with psychiatric disorders such as depressive symptoms, schizophrenia, delusions, hallucinations, or suicidal ideation.
- Patients with severe cardiovascular disease, including but not limited to New York Heart Association (NYHA) class II to IV congestive heart failure, or left ventricular ejection fraction (LVEF) < 50% or below the lower limit of normal.
- Patients with other conditions that, in the investigator's opinion, make the patient unsuitable for participation in this study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
Wuhan union hosptital
Wuhan, Hubei
Xiaoli Lan, PhD, +86-027-83692633, lxl730724@hotmail.com
About this study
This study is a single-center, open-label first-in-human clinical study. Patients with clinically suspected or confirmed malignant solid tumors will undergo [68Ga]Ga-FAP PET imaging or [177Lu]Lu-FAP SPECT imaging as well as [18F]FDG PET imaging to determine the presence or absence of lesions, and to assess lesion location, characteristics, and metastasis. Histopathological diagnosis or follow-up results will serve as the reference standard. The diagnostic efficacy of [68Ga]Ga-FAP PET imaging or [177Lu]Lu-FAP SPECT imaging for malignant tumors will be evaluated. Additionally, the study will analyze the biodistribution and dosimetry of [177Lu]Lu-FAP following a single administration, explore the correlation between tumor uptake values on imaging and immunohistochemical FAP expression levels, and evaluate the safety and tolerability of a single low-dose intravenous injection of [68Ga]Ga-FAP or [177Lu]Lu-FAP for diagnostic imaging.
- Conditions
- Malignant Neoplasm
- Being tested
- Novel FAP-targeted probe
- Medical subject headings
- Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Novel FAP-targeted probeDrug
For Cancer patients, subjects should have targeting FAP scans
| Study group | Role | What they receive |
|---|---|---|
| PET/SPECT imaging of novel FAP-targeted probe in malignant neoplasm | Experimental | This project aims to perform integrated SPECT/CT or PET/MR imaging in patients with histologically confirmed malignant neoplasms with high fibroblast activation protein (FAP) expression. This study utilizes a FAP-specific PET/SPECT imaging probe to evaluate the feasibility, accuracy, and clinical value in malignant neoplasm. Receives: Drug: Novel FAP-targeted probe |
What is being measured
The primary outcome is the main question the study is designed to answer.
Visual and standardized uptake values assessment of lesions and biodistribution
At least two experienced nuclear medicine physicians will analyze the images, using histopathological diagnosis or follow-up findings as the reference standard.The standardized uptake value (SUV) of tumor and organs will be measured after a semiquantitative analysis is conducted for each case.
Measured: 1 month
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jul 2026
- Study start30 Jul 2026 (estimated)
- Primary completion30 Sep 2026 (estimated)
- Study completion30 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malignant NeoplasmStudies of the same condition, open and under way.
- More trials run by Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Early Phase 1
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 20 participants (estimated)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07707999
- Sponsor's protocol ID
- Xlan-20251286
- Status last verified
- Jul 2026
- First submitted
- 14 Apr 2026
- Last updated
- 16 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Application of FAP-Targeted Radionuclide Imaging in the Diagnosis and Staging of Malignant Solid Tumors
- ClinicalTrials.gov ID
- NCT07707999
- Acronym / sponsor ID
- Xlan-20251286
- Conditions
- Malignant Neoplasm
- Phase
- Early Phase 1
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 20 participants (estimated)
- Lead sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyUniversity, hospital or other
- Study start
- 30 Jul 2026 (estimated)
- Primary completion
- 30 Sep 2026 (estimated)
- Study completion
- 30 Dec 2026 (estimated)
- First posted
- 16 Jul 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a single-center, open-label first-in-human clinical study. Patients with clinically suspected or confirmed malignant solid tumors will undergo [68Ga]Ga-FAP PET imaging or [177Lu]Lu-FAP SPECT imaging as well as [18F]FDG PET imaging to determine the presence or absence of lesions, and to assess lesion location, characteristics, and metastasis. Histopathological diagnosis or follow-up results will serve as the reference standard. The diagnostic efficacy of [68Ga]Ga-FAP PET imaging or [177Lu]Lu-FAP SPECT imaging for malignant tumors will be evaluated. Additionally, the study will analyze the biodistribution and dosimetry of [177Lu]Lu-FAP following a single administration, explore the correlation between tumor uptake values on imaging and immunohistochemical FAP expression levels, and evaluate the safety and tolerability of a single low-dose intravenous injection of [68Ga]Ga-FAP or [177Lu]Lu-FAP for diagnostic imaging.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| PET/SPECT imaging of novel FAP-targeted probe in malignant neoplasm | Experimental | Drug: Novel FAP-targeted probeThis project aims to perform integrated SPECT/CT or PET/MR imaging in patients with histologically confirmed malignant neoplasms with high fibroblast activation protein (FAP) expression. This study utilizes a FAP-specific PET/SPECT imaging probe to evaluate the feasibility, accuracy, and clinical value in malignant neoplasm. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Voluntary participation and the patient or their legal representative is able to sign an informed consent form.
- Adult patients (aged 18 or above), regardless of gender.
- Patients with an ECOG performance status of 0 to 1 and able to tolerate PET and SPECT/CT examinations.
- Patients with histopathologically or clinically confirmed malignant solid tumors who have measurable lesions according to RECIST 1.1 criteria.
- Patients with expected survival>6 months.
Key exclusion criteria (12 listed)
- Patients who are pregnant or breastfeeding, or plan to become pregnant during the study period or within three months after study drug administration (excluding those who have been postmenopausal for at least one year, or those who are surgically sterilized, such as bilateral tubal ligation without recanalization, bilateral oophorectomy, or hysterectomy); or patients who plan to donate sperm or eggs during the study period or within three months after study drug administration.
- Patients with known or suspected allergy to the investigational drug or any of its components, or patients with severe allergic constitution.
- Patients who have undergone procedures within 6 months prior to study entry that, in the investigator's judgment, may affect drug absorption, distribution, metabolism, or excretion.
- Patients with positive syphilis or HIV test results at screening.
- Patients with abnormal liver or kidney function: serum total bilirubin (TBIL) > 31.5 umol/L; aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 120 U/L, or > 200 U/L if the elevation is considered to be related to liver metastases from solid tumors; serum creatinine (Scr) > 150 umol/L, or creatinine clearance < 60 mL/min (according to the Cockcroft-Gault formula).
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Novel FAP-targeted probeFor Cancer patients, subjects should have targeting FAP scans | Drug | PET/SPECT imaging of novel FAP-targeted probe in malignant neoplasm |
Primary outcome
Visual and standardized uptake values assessment of lesions and biodistribution
Time frame: 1 month
At least two experienced nuclear medicine physicians will analyze the images, using histopathological diagnosis or follow-up findings as the reference standard.The standardized uptake value (SUV) of tumor and organs will be measured after a semiquantitative analysis is conducted for each case.
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Jul 2026.
Related trials for Malignant Neoplasm
Not yet recruitingPhase 1
Hepatic Artery Infusion of Carfilzomib in Participants With Liver Metastatic Disease Previously Treated With Hepatic Artery Infusion Pump Therapy
Colorectal Neoplasms, Neoplasms
RecruitingPhase 2
Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)
Multiple Myeloma
Not yet recruiting
Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer
Breast Cancer, Breast Neoplasms
RecruitingPhase 2
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm
RecruitingPhase 3
Somatostatin Analogues vs. Observation After Peptide Receptor Radionuclide Therapy (PRRT) in Nonfunctional Neuroendocrine Neoplasms
Neuroendocrine Neoplasm, Gastroenteropancreatic Neuroendocrine Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Early Phase 1 study testing Novel FAP-targeted probe in people with Malignant Neoplasm, run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 12 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 16 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Early Phase 1 (sometimes called Phase 0) studies give a very small amount of a treatment to a few people, mainly to see how the body handles it.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Xiaoli Lan, PhD (0086-027-83692633, lxl730724@hotmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Visual and standardized uptake values assessment of lesions and biodistribution (time frame: 1 month). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Jul 2026.